AdCOVID stimulated both strong serum neutralizing activity and potent mucosal IgA immunity in the respiratory tract.
BIRMINGHAM, Ala. – Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.
The studies — a collaboration between UAB and the Gaithersburg, Maryland-based Altimmune — showed strong serum neutralizing activity and potent mucosal IgA immunity in the respiratory tract. The induction of IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19. Based on these findings, AdCOVID is expected to be advanced to a Phase 1 safety and immunogenicity study in Q4 of this year.
AdCOVID is designed to express the receptor binding domain of the SARS-CoV-2 virus spike protein, a key immune target that is essential for the virus to bind to cells and initiate infection. By focusing the immune response to this portion of the viral spike protein, AdCOVID elicited a strong systemic antibody response against the receptor binding domain in mice, achieving serum IgG antibody concentrations greater than 800 micrograms per milliliter just 14 days after administration of a single intranasal dose. In addition, AdCOVID stimulated serum viral neutralization titers of 1:320 by Day 28, two-times higher than the titer recommended by the U.S. Food and Drug Administration for investigational convalescent plasma as a treatment for severe COVID-19.
In a separate study with UAB, a single intranasal dose of AdCOVID stimulated a 29-fold induction of mucosal IgA in bronchoalveolar fluid of vaccinated mice. This level of IgA antibody stimulation is well above that associated with protection from disease in clinical studies of other mucosal vaccines. Frances Lund, Ph.D., lead UAB investigator for preclinical testing of the AdCOVID vaccine candidates, said, “The potent stimulation of mucosal IgA immunity in the respiratory tract may be crucial to effectively block infection and transmission of the SARS-CoV-2 virus, given that the nasal cavity is a key point of entry and replication for the SARS-CoV-2 virus.”
“Stimulation of immunity at this level just 14 days after a single dose is impressive for any vaccine, and is particularly notable for a potential coronavirus vaccine,” said Lund, the Charles H. McCauley Professor and chair of the UAB Department of Microbiology. The Lund lab did the preclinical testing in collaboration with the labs of Troy Randall, Ph.D., professor of medicine in the UAB Division of Clinical Immunology and Rheumatology; Kevin Harrod, Ph.D., professor in the UAB Department of Anesthesiology and Perioperative Medicine; and three more UAB Department of Microbiology labs led by Rodney King, Ph.D., assistant professor, Todd Green, Ph.D., associate professor, and John Kearney, Ph.D., professor.
In other details from the collaborative preclinical work, Altimmune announced that the antibody responses were accompanied by a rapid recruitment of CD8+ T cells, CD4+ T cells, dendritic cells and natural killer cells in the respiratory tract. Increases in both germinal center and memory B cells, as well as T follicular helper cells, all associated in prior vaccine development research with the generation of long-lived antibody responses, were observed in regional lymph nodes and the spleen.
Preclinical data for the antigen-specific T cell response are expected in coming weeks, along with additional immunogenicity readouts.
The Altimmune-UAB collaboration was announced March 30, and Lund made that work the highest priority for her group. “The goal,” she said in March, “is to get the data to Altimmune as rapidly as possible, so they will use the information gained from the preclinical study to design their clinical trial in people.”
Intranasal dosing provides AdCOVID with the potential to be administered rapidly and without the need for needles, syringes or trained healthcare personnel. In addition, AdCOVID’s expected room temperature stability profile may allow for broad distribution of the vaccine without the need for expensive cold-chain logistics, such as refrigeration or freezing.
UAB has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
At UAB, Randall holds the William J. Koopman Endowed Professorship in Rheumatology and Immunology, Harrod holds the Benjamin Monroe Carraway, M.D., Endowed Chair in Anesthesiology, and Kearney holds the Endowed Professorship in Immunology.